Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Pretomanid/PA-824

Displaying 58 papers

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

Author(s): Denise Evans, Kamban Hirasen, Clive Ramushu, Lawrence Long, Edina Sinanovic, Francesca Conradie, Pauline Howell, Xavier Padanilam, Hannetjie Ferreira, Ebrahim Variaiva, Shakira Rajaram, Aastha Gupta, Sandeep Juneja, Norbert Ndjeka

10/2024

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Drug Market, TB Market

Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

Publication: The International Journal of Tuberculosis and Lung Disease

Author(s): D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja

6/2024

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, Regimen Change, TB Drug Market

Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China

Publication: Annals of Clinical Micobiology and Antimicrobials

Author(s): Bing Zhao, Huiwen Zheng, Juliano Timm, Zexuan Song, Shaojun Pei, Ruida Xing, Yajie Guo, Ling Ma, Feina Li, Qing Li, Yan Li, Lin Huang, Chong Teng, Ni Wang, Aastha Gupta, Sandeep Juneja, Fei Huang, Yanlin Zhao, Xichao Ou

5/2024

Tags: Drug-Sensitivity Testing, M.tb. Biology, MDR-TB, Pretomanid/PA-824, XDR-TB

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Publication: Lancet Infectious Diseases

Author(s): Muge Cevik, MD Lindsay C Thompson, MPhil Caryn Upton, MD Valéria Cavalcanti Rolla Mookho Malahleha, MD Blandina Mmbaga, PhD Nosipho Ngubane, MD Zamzurina Abu Bakar, MD Mohammed Rassool, MD Ebrahim Variava, MD Rodney Dawson, MD Suzanne Staples, DPhil Umes

5/2024

Tags: Clinical Development, Clinical Trial Results, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

Publication: PLOS One

Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu

1/2024

Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

Publication: PLOS Global Public Health

Author(s): Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

Publication: Clinical Infectious Diseases

Author(s): Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta, Linh Nguyen, Samuel Schumacher, Tim Schlub, Greg Fox

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer

Publication: Molecular Pharmaceutics

Author(s): Hanh Thuy Nguyen, Tu Van Duong, Sarah Jaw-Tsai, Rebecca Bruning-Barry, Poonam Pande, Rajneesh Taneja, and Lynne S. Taylor

5/2023

Tags: Pretomanid/PA-824, TB Drug Market, Underserved Populations

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

Publication: Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

3/2023

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Stable sugar and sugar-free suspensions of pretomanid

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., Hesseling, A. C.

12/2022

Tags: BENEFIT Kids, Childhood TB, Pretomanid/PA-824, Underserved Populations

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Publication: Clinical Pharmacokinetics

Author(s): Yuanxi Zou, Jerry Nedelman, Antonio Lombardi, Frances Pappas, Mats O Karlsson, Elin M Svensson

11/2022

Tags: Pharmacokinetics, Pretomanid/PA-824

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

Publication: PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

11/2022

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Publication: New England Journal of Medicine

Author(s): Francesca Conradie, et al., for the ZeNix Trial Team

9/2022

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, XDR-TB

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice

Publication: International Journal of Toxicity

Author(s): Jeffrey L Ambroso, John Dillberger, Rebecca Bruning-Barry, Tian Yang

7/2022

Tags: Pretomanid/PA-824

Male reproductive hormones in patients treated with pretomanid

Author(s): Boekelheide K, Olugbosi M, Nedelman J, Everitt D, Smith E, Betteridge M, Sun E, Spigelman M

6/2022

Tags: MDR-TB, Pretomanid/PA-824, XDR-TB

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys

Publication: Toxicology Reports

Author(s): Rebecca Bruning-Barry, Jeffrey L.Ambroso, John Dillberger, Tian J.Yang

4/2022

Tags: Pretomanid/PA-824

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

Publication: Antimicrobial Chemotherapy

Author(s): Anna Bateson, Julio Ortiz Canseco, Timothy D McHugh, Adam A Witney, Silke Feuerriegel, Matthias Merker, Thomas A Kohl, Christian Utpatel, Stefan Niemann, Sönke Andres, Katharina Kranzer, Florian P Maurer, et al.

3/2022

Tags: Drug-Sensitivity Testing, Pretomanid/PA-824

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Publication: BMC Public Health

Author(s): S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra et al

7/2021

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, TB Drug Market, TB Market, XDR-TB

Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts

Author(s): S. Oelofse, A. Esmail, A. H. Diacon F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda

4/2021

Tags: Bedaquiline (TMC-207), Linezolid, MDR-TB, Pretomanid/PA-824

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): C. D. Tweed, G. H. Wills, A. M. Crook

3/2021

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide, STAND/NC-006

Pages